Virbac: 2025 annual results

Virbac SA (0NM7, AIM) has reported its 2025 annual results, showcasing a solid performance characterized by organic revenue growth of 7.9% at constant exchange rates, culminating in total revenues of €1,464.7 million. This growth trajectory is attributed to a volume/mix effect of approximately 5%, supplemented by a price increase of around 3%. The adjusted EBIT margin stood at 16.3%, reflecting a slight decline from the previous year's 16.6%, primarily due to a temporary shutdown of an antigen production site and higher inventory write-offs. However, these challenges were offset by a robust underlying performance in sales prices and product mix, alongside an improved operating expense to revenue ratio. Consolidated net income rose by 3.2% to €150.5 million, supported by strong cash generation of €93 million, which was instrumental in funding the acquisition of Thyronorm while maintaining net debt at a stable €172.8 million, up from €168.5 million at the end of 2024.

The results for 2025 indicate a resilient operational framework, with the company poised to continue its growth trajectory into 2026. Virbac anticipates revenue growth of between 5.5% and 7.5% at constant rates and scope, alongside an adjusted recurring operating income margin projected to be around 17%. The strategic acquisition of Thyronorm, which complements Virbac's portfolio in high unmet need areas, underscores the company's commitment to enhancing its product offerings and market position. The financial strength demonstrated through cash generation and low debt levels provides a solid foundation for further investments in research and development, as well as capital expenditures aimed at industrial transformation.

Financially, Virbac's market capitalisation remains robust, although specific figures for the current market cap were not disclosed in the announcement. The company reported shareholders' equity of €1,125.2 million, which reflects a 7.9% increase from the previous year. The net debt position, while slightly elevated, remains manageable, and the operating cash flow before interest and taxes increased by 3.1% to €289.1 million. This financial stability suggests that Virbac is well-positioned to fund its ongoing operational needs and strategic initiatives without immediate concerns regarding liquidity.

In terms of valuation, Virbac's adjusted EBIT margin of 16.3% at constant exchange rates positions it competitively within its sector. However, without direct peers specified in the announcement, it is essential to identify comparable companies in the same market cap tier and sector. Given that Virbac operates within the animal health sector, potential peers include companies such as IDEXX Laboratories Inc. (NASDAQ:IDXX), Zoetis Inc. (NYSE:ZTS), and Elanco Animal Health Inc. (NYSE:ELAN). These companies, while larger in market capitalisation, provide a benchmark for evaluating Virbac's performance metrics. For instance, Zoetis has an adjusted EBIT margin of approximately 30%, significantly higher than Virbac's, indicating a potential area for improvement in operational efficiency.

Execution-wise, Virbac's management has demonstrated a consistent ability to meet operational targets, although the recent temporary production shutdown raises questions about the resilience of its supply chain. The company's historical performance suggests a strong track record in navigating challenges, but the recent inventory write-offs could signal underlying issues that warrant closer scrutiny. Furthermore, the reliance on acquisitions for growth, as evidenced by the Thyronorm deal, introduces integration risks that could impact future performance if not managed effectively.

A specific risk highlighted by the announcement is the potential for disruptions in production, as seen with the antigen production site shutdown. This incident not only affects current output but may also have longer-term implications for product availability and market share, particularly in competitive segments. Additionally, the company's reliance on external acquisitions for growth could expose it to integration challenges and market volatility, particularly in the face of changing regulatory environments.

Looking ahead, the next measurable catalyst for Virbac is the anticipated revenue growth guidance for 2026, which is expected to be disclosed in the upcoming quarterly results. This guidance will provide further clarity on the company's trajectory and its ability to sustain growth in a potentially volatile market environment.

In conclusion, Virbac's 2025 annual results reflect a solid operational performance with a moderate growth outlook for 2026. The company's financial position appears stable, supported by strong cash generation and manageable debt levels. However, the risks associated with production disruptions and reliance on acquisitions for growth cannot be overlooked. Overall, the announcement can be classified as moderate in terms of materiality, as it reinforces the company's existing strategic direction while highlighting areas for potential improvement in operational execution and risk management.

Key insights

• ●Virbac's revenue grew 7.9% in 2025, reaching €1,464.7 million.
• ●Net debt remains stable at €172.8 million, supporting strategic investments.
• ●2026 revenue growth is projected between 5.5% and 7.5%.

Disagree with this article?